You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CEFTRIAXONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ceftriaxone, and when can generic versions of Ceftriaxone launch?

Ceftriaxone is a drug marketed by Acs Dobfar, Agila Speclts, Aurobindo Pharma Ltd, Bedford, Facta Farma, Fresenius Kabi Usa, Hospira Inc, Lupin, Qilu, Samson Medcl, Sandoz, Sandoz Inc, Teva, Wockhardt, Astral, Cephazone Pharma, Deva Holding As, Epic Pharma Llc, Hikma Farmaceutica, Teva Pharms Usa, B Braun, Baxter Hlthcare, Anda Repository, and Hikma. and is included in thirty-seven NDAs.

The generic ingredient in CEFTRIAXONE is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ceftriaxone

A generic version of CEFTRIAXONE was approved as ceftriaxone sodium by ANDA REPOSITORY on January 20th, 2017.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CEFTRIAXONE?
  • What are the global sales for CEFTRIAXONE?
  • What is Average Wholesale Price for CEFTRIAXONE?
Drug patent expirations by year for CEFTRIAXONE
Drug Prices for CEFTRIAXONE

See drug prices for CEFTRIAXONE

Recent Clinical Trials for CEFTRIAXONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tata Memorial CentrePhase 2
Ministry of Health, FrancePhase 3
Assistance Publique Hopitaux De MarseillePhase 3

See all CEFTRIAXONE clinical trials

Pharmacology for CEFTRIAXONE

US Patents and Regulatory Information for CEFTRIAXONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065169-002 May 9, 2005 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Deva Holding As CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 210197-001 Jan 12, 2024 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bedford CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065465-004 Aug 18, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Anda Repository CEFTRIAXONE SODIUM ceftriaxone sodium INJECTABLE;INJECTION 091117-001 Jan 20, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065245-003 Feb 15, 2006 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.